• Home
  • CML Experts
    • Team of experts on CML who developed imatinib >
      • Dr. Elisabeth Buchdunger
      • Dr. Brian Druker
      • Dr. John Goldman
      • Dr. Nora C. Heisterkamp
      • Dr. David Hungerford
      • Dr. Nicholas Lydon
      • Dr. Alex Matter
      • Dr. Felix Mitelman
      • Dr. Peter C. Nowell
      • Dr. Carlo Gambacorti-Passerini
      • Dr. Moshe Talpaz
      • Dr. Janet D. Rowley
      • Dr. Charles Sawyers
      • Dr. Jürg Zimmermann
      • Dr. Owen Witte
    • Experts involved in developing dasatinib >
      • Dr. Jagabandhu Das
    • Experts involved in developing nilotinib
    • Other CML experts in America >
      • Other CML experts in Canada >
        • Dr. Sarit Assouline
        • Dr. Lambert Busque
        • Dr. Robert Delage
        • Dr. Connies Eaves
        • Dr. Josée Hébert
        • Dr. Pierre Laneuville
        • Dr. Isabelle Bence-Bruckler
        • Dr. Jeffrey H Lipton
        • Dr. Luigina Mollica
      • Other CML experts in US >
        • Carolyn Blasdel, RN , FNP-BC, OCN
        • PATRICIA JAKEL, RN, MN, AOCN
        • Rey Garcia, RN, BSN
        • Dr. Ravi Bhatia
        • Dr. Jorge E. Cortes
        • Dr. Arul Chinnaiyan
        • Dr. Michael Deininger
        • Dr. James D. Griffin
        • Dr. Frank Giles
        • Dr. Elias J. Jabbour
        • Dr. Hagop Kantarjian
        • Dr. Harry P. Erba
        • Dr. Richard A. Larson
        • Dr. Alison Loren
        • Dr. Michael Mauro
        • Dr. Stephen D. Nimer
        • Dr. Ruben A. Mesa
        • Dr. Susan M. O'Brien
        • Dr. Jerald P. Radich
        • Dr. Karen Seiter
        • Dr. Neil Shah
        • Dr. Richard Stone
        • Dr. Raoul Tibes
        • Dr. Bin Zhang
      • Other CML experts in South America >
        • Dra Beatriz Moiraghi
        • Dr Carolina Pavlovsky
    • Other CML Experts in Europe >
      • Dr. Jane Apperley
      • Dr. Michele Baccarani
      • Pr. Agnès Buzyn
      • Dr. Gabriel Etienne
      • Dr. Marie-Joëlle Mozziconacci
      • Dr. François Guilhot
      • Dr. Eliane Gluckman
      • Dr. Andreas Hochhaus
      • Dr. Martin Müller
      • Dr. Stephen O'Brien
      • Stéphane Prost
      • Dr. Tessa L Holyoake
      • Dr. Hana Klamova
      • Dr. Jeroen J.W.M. Janssen
      • Dr. Franck-Emmanuel Nicolini
      • Dr. Delphine Rea
      • Dr. Johan Richter
      • Dr. Philippe Rousselot
      • Dr. Giuseppe Saglio
      • Dr. François-Xavier Mahon
      • Pr Gregor Verhoef
    • Other CML experts in Asia >
      • Dr. Charles Chuah
      • Dr. Goh Yeow Tee
      • Dr. Pankaj Malhotra
      • Dr. Hemant Malhotra
      • Dr. Kim Dong-Wook
    • Other CML experts in Africa >
      • Dr. Anthony Oyekunle
    • Other CML experts in Australia >
      • Dr. Susan Branford
      • Pr Tim Hughes
      • Dr. Anthony P Schwarer
  • Medical Concepts
    • Introduction to CML
    • Blood
    • Bone Marrow
    • DNA
    • Immune System >
      • Natural killer cell - NK
      • T Cells
    • JAK2 Gene
    • Treatment response in CML
    • Polymerase Chain Reaction >
      • Dr. Kary Bank Mullis
    • Stem Cells
    • Donor lymphocyte infusion (DLI)
    • Blood-Brain Barrier
    • Interferon regulatory factor 8 (IRF8)
    • Myeloproliferative disorders (MPD) >
      • Introduction to CML
      • Essential Thrombocythemia (ET)
      • Myelofibrosis (MF)
      • Polycythemia Vera (PV)
    • Types of leukemia >
      • Atypical chronic myeloid leukemia
  • Medication
    • Hydroxyurea
    • Interferon Alpha
    • Gleevec (Imatinib) >
      • Generic Gleevec (Imatinib)
    • Tasigna (Nilotinib)
    • Sprycel (Dasatinib)
    • Bosulif (Bosutinib)
    • Iclusig (Ponatinib)
    • Supect (Radotinib)
    • ABL001 (Asciminib)
    • Synribo (Omacetaxine )
    • Jakafi (Ruxolitinib)
    • Flumatinib
    • (Bafetinib)
    • (Danusertib)
    • (Rebastinib)
    • BGB324
    • PF-114
    • NEV-801
    • BP1001
    • HQP1351
    • K0706
    • Vidaza (Azacitidine)
  • Managing side effects
    • List of side effets >
      • Bone Pain
      • Depression
      • Eyes
      • Ear
      • Fatigue
      • Fluid Retention
      • Gastrointestinal system
      • Hair
      • Heart
      • Hepatotoxicity
      • Kidney
      • Muscle cramping
      • Peripheral arterial disease in CML
      • Pleural effusion
      • Pulmonary arterial hypertension
      • Thyroid dysfunction
      • Skin
      • Weight gain
    • CML and Nutrition
    • Psycho-Oncology
    • Complementary and Alternative Medicine >
      • Art Therapy >
        • Art Therapist
        • CMLer's portofolio
      • Music therapy >
        • YouTube creation by CMLer's family
        • Magnificent (I Believe)
        • Adagio for Strings (Samuel Barber)
      • Yoga
      • Physical Activity
      • Zootherapy
  • Patient Testimonials
    • Virginia Garner
    • Pat Elliott
    • Jan Geissler
    • Kris
    • Nigel
    • Katie
    • Mel Mann
    • Tamera Simonson
    • Hans Loland
    • Alyssa
    • Brown Dudley
    • Erin Havel (Author)
    • Erin Zammett Ruddy
    • Rob Shick
    • Gary Gonzales
    • Ron Robbecke
    • Drew Johnston
    • Angela Tyrrell
    • Doug Jenson
    • Rich Jones
    • Kevin Williams
    • Jean McGlynn
    • Austin Granatowicz
    • Tom Cleaver
    • Others testimonials
    • Some celebrities >
      • Alexa Score
      • Laura Boyd
      • Dr. Richard Rockefeller
      • Tim Holcomb
      • Doris Muramatsu
      • Ryan O'Neal
      • Charlie Schlatter
      • Kelvin Alston
      • Kareem Abdul-Jabar
      • Carlos Carrasco
      • Jason Blake
      • Brian Boyle
      • Roman Reigns
      • Rick Upchurch
    • Bud Romine - the first patient
    • Kayla Naton (Pregnancy)
    • Suzan Mc Namara and the petition
  • Blogs
    • Access CML Drugs
    • Trey's CML Leukemia Blog
    • Living with CML
    • CMKID's blog – Dislodging the bullet
    • CML Recovery - Stopping KTI
    • Hans's Blog
    • Elizabeth's Blog - my leukemia journey
    • Elizabeth's Blog - Heart of the rose
    • Ian's Blog
    • Joe's Blog
    • Jon's Blog
    • Josh's Blog
    • Mannan's Blog
    • Justin Ozuna's Blog
    • Lindsey's Blog
    • Matt's Blog
    • Matthew's Blog
    • Michelle's Blog
    • Michelle D's Blog
    • Nayree's Blog
    • Rob's Blog
  • News on CML (Chronic myeloid leukemia)
    • English
    • English- Archives 2017-2016
    • English - Archives 2015-2001
    • French (Français)
    • Spanish (Español)
  • Various topics
    • You’ve just been diagnosed
    • History of CML
    • Cure possible for CML? >
      • Hematopoietic stem cell transplantation using single UM171-expanded cord blood
      • Inhibitory effect of c-Myc on p53-induced apoptosis in leukemia cells
      • Inhibition of the protein Ezh2 can cure CML?
      • Combination of ruxolitinib with tyrosine kinase inhibitor
      • Combination of pioglitazone with tyrosine kinase inhibitor
      • Combination of miristen with tyrosine kinase inhibitor
      • Combination of Inecalcitol with tyrosine kinase inhibitor
      • Combination of dasatinib plus Nivolumab
      • Combination of Pembrolizumab with tyrosine kinase inhibitor
      • Combination of interferon with tyrosine kinase inhibitor
      • Combination of Venetoclax with tyrosine kinase inhibitor
      • PROTAC-mediated Targeted Protein Degradation
      • Inhibition of STAT5 in conjunction with standard TKI therapy
      • CML vaccine
      • Can immunotherapy cure leukemia?
      • Chimeric Antigen Receptor T-Cell Therapy
      • Can genetic sequencing help to cure leukemia?
      • Natural Medicine >
        • Possible cure for CML in Fish Oil
        • Betel leaf may help fight CML
        • Feverfew extract (parthenolide)
        • Can dandelions kill cancer?
        • Can curcumin cure leukemia?
      • Can the new drug CX-5461 cure leukemia?
      • CRISPR-Cas9 gene-editing technique
      • Presence of bcr abl fusion transcripts in healthy individua
      • Math could help cure leukemia
    • Treatment free remission (TFR ) >
      • The French trial called STIM (Stop Imatinib)
      • De-escalation of treatment
      • Tyrosine Kinase Inhibitor Withdrawal Syndrome in CML Patients
    • CML causes
    • CML and pregnancy
    • Children with CML
    • Food and Drug Interactions
    • Bone marrow transplant
    • CML Blast Crisis treatment
    • Stem cells from umbilical cord blood
    • Mutation T315I
    • Sensitive detection of BCR-ABL1 mutations
    • Elderly patients with CML
    • Living with CML and diabetes
    • Non-adherence of CML patients
    • Vaccination of CMLers
    • Sports with CML
    • Pronostic, life expectancy, quality of life, ..... in chronic myeloid leukemia
    • CML Awareness Day
    • The movie "Dying to Survive"
  • Congresses, conferences, meetings ASH, ASCO, EHA ...
    • ASCO - American Society of Clinical Oncology >
      • ASCO 2019 - Chicago
      • ASCO 2018 - Chicago
      • ASCO 2017 - Chicago
      • ASCO 2016 - Chicago
      • ASCO 2015 - Chicago
      • ASCO 2014 - Chicago
      • ASCO 2013 - Chicago
      • ASCO 2012 - Chicago
      • ASCO 2011 - Chicago
      • ASCO 2010 - Chicago
    • ASH - American Society of Hematology >
      • ASH 2019- Orlando
      • ASH 2018 - San Diego
      • ASH 2017 - Atlanta
      • ASH 2016 - San Diego
      • ASH 2015 - Orlando
      • ASH 2014 - San Francisco
      • ASH 2013 - New Orleans
      • ASH 2012 - Atlanta
      • ASH 2011 - San Diego
      • ASH 2010 - Orlando
      • ASH 2009 - New Orleans
    • BTG - Bridging the Gap >
      • BTG 2011 - Singapore (Singapore)
    • CML & MPDs - UK National Meetings
    • CML Horizons >
      • CML Horizon 2018 -Warsaw (Pologna)
      • CML Horizon 2017- Frankfurt (Germany)
      • CML Horizon 2016 - Ljubljana (Slovenia)
      • CML Horizons 2015 - (Barcelona, Spain)
      • CML Horizons 2014 - ( Belgrade, Serbia)
      • CML Horizons 2013 - (Prague - Czech Republic)
      • CML Horizons 2012 - (Munich, Germany)
      • CML Horizons 2011 - (Amsterdam - The Netherlands)
    • EHA - European Hematology Association >
      • EHA 2019 - Amsterdam (Netherlands)
      • EHA 2018 - Stockholm(Sweden)
      • EHA 2017 - Madrid (Spain)
      • EHA2016-Copenhagen,(Denmark)
      • EHA 2015 - Vienne (Austria)
      • EHA 2014 - Milan (Italy)
      • EHA 2013 - Stockholm (Sweden)
      • EHA 2012 - Amsterdam (The Netherlands)
      • EHA 2011 - London (England)
      • EHA 2010 - Cascais (Portugal)
      • EHA 2009 - Berlin (Germany)
      • EHA 2008 - Copenhague (Danemark)
    • ESH - European School of Haematology >
      • ESH 2016 - Houston - USA
      • ESH 2015 - Estoril - Portugal
      • ESH 2014 - Philadelphia
  • Educational videos
    • Educational videos (in English)
    • Educación de vídeos en español (in Spanish)
    • Vidéos pédagogiques en français (in French)
  • Educational events
  • CML Glossaries
  • Professionnel help and literature
  • International publications
    • Publications from Africa
    • Publications from America
    • Publications from Australia
    • Publications from Asia
    • Publications from Europe
  • Specialist Journals in Hematology/Oncology
  • Patient Rights
  • Moral Support
    • Where to get help and support
    • Family support
    • I Had Cancer: You are not alone
    • I’m A Doctor With Chronic Illness. Here Are 12 Things I Wish People Knew
    • 23 Nice Things You Can Do for Someone With Cancer
    • The march toward healing
    • Be happy
    • Dances at the Cancer Research Centre
    • The spoon theory
    • Stronger
    • Magnificent - Beauty of nature
  • Links to other sites, forums and Facebook
    • Sites ( English and other languages)
    • Forums
    • CML on Facebook
    • CML on Twitter
    • Audio Podcast
  • Awards & Recognition
  • Foundations
    • Leukemia Foundations >
      • American Cancer Society
    • Hospital Foundations
  • SPECIAL Donation
  • About us
    • Guestbook
    • Contact us
Chronic Myeloid Leukemia

ASH 2012  -   Atlanta  -   CML   -   Chronic Myeloid Leukemia
                           


2012 ASH Annual Meeting and Exposition      December 8-11, 2012


"iCMLf Forum" at ASH for physicians from emerging regions

CML Program 

Saturday, December 8, 2012

631. Chronic Myeloid Leukemia - Biology and Pathophysiology, excluding Therapy II
Chronic Myeloid Leukemia: The Pristine Paradigm for Successful Targeted Therapy
631. Chronic Myeloid Leukemia - Biology and Pathophysiology, excluding Therapy: Poster I
632. Chronic Myeloid Leukemia - Therapy: Poster I

Sunday, December 9, 2012

Chronic Myeloid Leukemia: The Pristine Paradigm for Successful Targeted Therapy
Does the Stem Cell Survive Tyrosine Kinase Inhibitors in Chronic Myeloid Leukemia and, If So, How?
632. Chronic Myeloid Leukemia - Therapy: Aiming for Deep Response
632. Chronic Myeloid Leukemia - Therapy I
631. Chronic Myeloid Leukemia - Biology and Pathophysiology, excluding Therapy: Poster II
632. Chronic Myeloid Leukemia - Therapy: Poster II

Monday, December 10, 2012

632. Chronic Myeloid Leukemia - Therapy: Pharmacodynamic Markers and Novel Treatment Approaches
631. Chronic Myeloid Leukemia - Biology and Pathophysiology, excluding Therapy: Poster III
632. Chronic Myeloid Leukemia - Therapy: Poster III 
901. Health Services and Outcomes Research: Poster III  (abstract no
4234, 4236, 4237, 4260, 4274, 4279)

Tuesday, December 11, 2012

631. Chronic Myeloid Leukemia - Biology and Pathophysiology, excluding Therapy I
632. Chronic Myeloid Leukemia - Therapy II


ASH 2012 NEWS

A CML Advocate's Perspective on News from ASH 2012              VIDEO
December 21, 2012, Patient Power

Study Brings Positive Results For the Most Resistant Types of CML   VIDEO
December 12, 2012, Patient Power

ASH: Higher Imatinib Exposures  Associated with Better Chronic-Phase CML Outcomes
December 11, 2012, Chemotherapy  advisor

ASH: Updated PACE Findings Uphold Ponatinib Benefit in CML and  Ph+ ALL
December 11, 2012, Cancer  Network

Learning about  CML
December 11, 2012, Cure Today

Ponatinib Works in CML When Nothing Else Is  Effective
December 11, 2012, Medscape Today  News

Temple scientists target DNA repair to eradicate leukemia stem cells
December 9, 2012, MedicalXpress

RAD52-Dependent Synthetic Lethality Eradicates Leukemia Stem  Cells
December 9, 2012, ASH  2012

Ariad drug proves effective in curbing chronic leukemia in study
December 9, 2012, Reuters
 
Novel therapeutic agents provide hope for patients with hard-to-treat blood disorders
December 9, 2012, Science  Codex

ASH 2012: Ponatinib for CML and Philadelphia chromosome-positive  acute lymphoblastic leukaemia
December 9, 2012, ecancernews

Is going for cure in chronic myeloid leukemia possible and justifiable?
December 8, 2012, Hematology

Understanding Why MDS Patients Have  Anemia                 VIDEO
December 8, 2012, Patient  Power
                           

NOTES
​ 

Abstracts and notes on CML presentations by Prof Steve O’Brien
2012, SPIRIT2, NewCastle Universisty

Forums and Patient associations'reports

ASH 2012  News by the CML Advocates Network 
ASH 2012 by  Cmlsupport (UK)
ASH 2012 by  AsianCMLSupportGroup
ASH 2012 by the National CML Society (US)
ASH Reports 2012 by CML Society of Canada


SOME INTERESTING ABSTRACTS FOR CML


Activation Levels of Natural Killer Cells and CD8+ T Cells Correlate Highly with Sustained Complete Molecular Response After Discontinuation of Imatinib in Chronic Myeloid Leukemia Patients

Early Molecular Response and Female Sex Strongly Predict Achievement of Stable Undetectable BCR-ABL1, a Criterion for Imatinib Discontinuation in Patients with CML

Patient Preferences for Stopping Tyrosine Kinase Inhibitors in  Chronic Myeloid Leukemia

The International Registry for Chronic Myeloid Leukemia (CML) in Children and Adolescents (I-CML-Ped-Study): Objectives and Preliminary Results

Chaetocin Exhibits Anti-Leukemia Activity Against Chronic Myeloid Leukemia Stem Cells

Clarithromycin Enhances tyrosine Kinase Inhibitor – Induced Cell Death by Inhibition of Late Stage Autophagy in Patients with Chronic Myeloid Leukemia At Diagnosis or with Resistant Stage of Disease

Sabutoclax, a Novel Pan BCL2 Family Inhibitor, Sensitizes Dormant  Blast Crisis Chronic Myeloid Leukemia Stem Cells to  Dasatinib

Five-Year Results of Nilotinib 400 Mg BID in Early Chronic Phase Chronic Myeloid Leukemia (CML): High Rate of Deep Molecular Response - Update of the Gimema CML WP Trial CML0307

Progressive Peripheral Arterial Occlusive Disease and Other Vascular Events During Nilotinib Therapy in Chronic Myeloid Leukemia

Dasatinib Therapy Affects Bone Homeostasis in Patients with Chronic Myelogenous Leukemia in Chronic Phase Independently of Molecular Response

Incidence of Hyperglycemia by 3 Years in Patients (Pts) with Newly Diagnosed Chronic Myeloid Leukemia in Chronic Phase (CML-CP) Treated with Nilotinib (NIL) or Imatinib (IM) in ΕΝΕSΤnd

Effects of Tyrosine Kinase Inhibitors On Spermatogenesis and Pituitary Gonadal Axis in Males with Chronic Myeloid Leukemia

A Sensitive Replicate RQ-PCR of BCR ABL Transcripts Suggests That A Large Portion of Long Term Post Allogeneic SCT CML Patients Are in Deep MR and May Therefore Be Cured From Their Disease

Complete Molecular Remission (CMR 4.5) of CML Is Induced Faster by Dose – Optimized Imatinib and Predicts Better Survival - Results From the Randomized CML-Study IV

Long-Term Anti-Leukemic Activity of Ponatinib in Patients with Philadelphia Chromosome-Positive Leukemia: Updated Results from an Ongoing Phase 1 Study

A Pivotal Phase 2 Trial of Ponatinib in Patients with Chronic Myeloid Leukemia (CML) and Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia (Ph+ALL) Resistant or Intolerant to Dasatinib or Nilotinib, or with the T315I BCR-ABL Mutation: 12-Month Follow-up of the PACE Trial

Bosutinib As Therapy for Chronic Phase Chronic Myeloid Leukemia Following Resistance or Intolerance to Imatinib: 36-Month Minimum Follow-up Update

Bosutinib As Therapy for Chronic Phase Chronic Myeloid Leukemia Following Failure with Imatinib Plus Dasatinib and/or Nilotinib: 24-Month Minimum Follow-up Update

Efficacy and Safety of Radotinib in Chronic Phase Chronic Myeloid Leukemia Patients with Resistance or Intolerance to BCR-ABL Tyrosine Kinase Inhibitors: Radotinib Phase 2 Clinical Trial

Natural History and Potential for Cure of Patients with Chronic Myeloid Leukemia in Chronic Phase Receiving Frontline Therapy with Recombinant Interferon-Alfa: 30-Year Update From M.D. Anderson Cancer Center

Clinical Significance of Deeper Molecular Responses with Four Modalities of Tyrosine Kinase Inhibitors As Frontline Therapy for Chronic Myeloid Leukemia

Incidence of Late Chronic Anemia in  Newly Diagnosed Patients with Chronic Myelogenous Leukemia Responsive to  Imatinib

Fatigue Is the Major Aspect Compromising Health-Related Quality of Life of Chronic Myeloid Leukemia Patients Receiving  Long-Term Imatinib Therapy

TWITTER

ASH2012 


                                   Return to other ASH Annual Meetings 


          (See our disclaimer - Voir notre avis de non-responsabilité- Vea nuestro aviso legal).

Copyright © 2010-2019 CMLeukemia.com
DMCA.com Protection Status